KLRG2 and cancer: Pan-cancer analysis utilizing TCGA and GTEx databases revealed significant overexpression of KLRG2 across multiple malignancies, including EC, ovarian cancer, cervical cancer, bladder cancer, breast cancer, esophageal carcinoma, testicular cancer, and lung adenocarcinoma (Figure 1A).